These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 26418882)
21. Advances in functional neuroimaging methodology for the study of brain systems underlying human neuropsychological function and dysfunction. Stern E; Silbersweig DA J Clin Exp Neuropsychol; 2001 Feb; 23(1):3-18. PubMed ID: 11320442 [TBL] [Abstract][Full Text] [Related]
23. Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi-quantitative 7.0 T magnetic resonance imaging study. De Reuck JL; Deramecourt V; Auger F; Durieux N; Cordonnier C; Devos D; Defebvre L; Moreau C; Caparros-Lefebvre D; Leys D; Maurage CA; Pasquier F; Bordet R Eur J Neurol; 2014 Jul; 21(7):1026-31. PubMed ID: 24698410 [TBL] [Abstract][Full Text] [Related]
24. The application of positron emission tomography (PET) imaging in CNS drug development. Suridjan I; Comley RA; Rabiner EA Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405 [TBL] [Abstract][Full Text] [Related]
25. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Gladman M; Cudkowicz M; Zinman L Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423 [TBL] [Abstract][Full Text] [Related]
26. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development. Soares HD Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975 [TBL] [Abstract][Full Text] [Related]
28. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms. Liu T; Bitan G ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134 [TBL] [Abstract][Full Text] [Related]
29. Answering the call: the influence of neuroimaging and electrophysiological evidence on rehabilitation. Boyd LA; Vidoni ED; Daly JJ Phys Ther; 2007 Jun; 87(6):684-703. PubMed ID: 17429001 [TBL] [Abstract][Full Text] [Related]
30. Combining magnetoencephalography and functional magnetic resonance imaging. Mathiak K; Fallgatter AJ Int Rev Neurobiol; 2005; 68():121-48. PubMed ID: 16443012 [No Abstract] [Full Text] [Related]
31. Life sciences: Biomarkers on the brain. Katsnelson A Nature; 2011 Nov; 479(7371):139-40. PubMed ID: 22103003 [No Abstract] [Full Text] [Related]
33. The neural systems that mediate human perceptual decision making. Heekeren HR; Marrett S; Ungerleider LG Nat Rev Neurosci; 2008 Jun; 9(6):467-79. PubMed ID: 18464792 [TBL] [Abstract][Full Text] [Related]
34. Functional biomarkers for neurodegenerative disorders based on the network paradigm. Horwitz B; Rowe JB Prog Neurobiol; 2011 Dec; 95(4):505-9. PubMed ID: 21801801 [TBL] [Abstract][Full Text] [Related]
35. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets. Jekunen A Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229 [TBL] [Abstract][Full Text] [Related]
37. Introduction: Neuroimaging of degenerative and traumatic encephalopathies. Law M; Wintermark M; Liu C; Van Horn JD Neurosurg Focus; 2015 Nov; 39(5):E1. PubMed ID: 26646925 [No Abstract] [Full Text] [Related]
38. Degeneration of the brainstem. Palacios Bote R; Fernández-Gil MA Semin Ultrasound CT MR; 2013 Apr; 34(2):142-52. PubMed ID: 23522779 [TBL] [Abstract][Full Text] [Related]
39. Nanotechnology for neurodegenerative disorders. Re F; Gregori M; Masserini M Nanomedicine; 2012 Sep; 8 Suppl 1():S51-8. PubMed ID: 22640910 [TBL] [Abstract][Full Text] [Related]